Page 142 - 《中国药科大学学报》2025年第4期

538 学报 Journal of China Pharmaceutical University 2025, 56(4): 531 − 538 第 56 卷

trial[J]. Lancet Infect Dis, 2023, 23(11): 1266-1279. Plasmodium vivax Duffy-binding protein induces strain-tran-
[30] Scaria PV, Roth N, Schwendt K, et al. mRNA vaccines express- scending antibodies[J]. JCI Insight, 2017, 2(12): e93683.
ing malaria transmission-blocking antigens Pfs25 and Pfs230D1 [41] Hou MM, Barrett JR, Themistocleous Y, et al. Vaccination with
induce a functional immune response[J]. NPJ Vaccines, 2024, Plasmodium vivax Duffy-binding protein inhibits parasite
9(1): 9. growth during controlled human malaria infection[J]. Sci Transl
[31] Hayashi CTH, Cao Y, Clark LC, et al. mRNA-LNP expressing Med, 2023, 15(704): eadf1782.
PfCSP and Pfs25 vaccine candidates targeting infection and [42] Kunkeaw N, Nguitragool W, Takashima E, et al. A Pvs25 mR-
transmission of Plasmodium falciparum[J]. NPJ Vaccines, NA vaccine induces complete and durable transmission-block-
2022, 7(1): 155. ing immunity to Plasmodium vivax[J]. NPJ Vaccines, 2023,
[32] Yusuf Y, Yoshii T, Iyori M, et al. Adeno-associated virus as an 8(1): 187.
effective malaria booster vaccine following adenovirus
[43] Balam S, Miura K, Ayadi I, et al. Cross-reactivity of rPvs48/45,
priming[J]. Front Immunol, 2019, 10: 730.
a recombinant Plasmodium vivax protein, with plasma from
[33] Alkema M, Smit MJ, Marin-Mogollon C, et al. A Pfs48/45-
Plasmodium falciparum endemic areas of Africa[J]. PLoS One,
based vaccine to block Plasmodium falciparum transmission:
2025, 20(3): e0302605.
phase 1, open-label, clinical trial[J]. BMC Med, 2024, 22(1):
[44] El-Moamly AA, El-Sweify MA. Malaria vaccines: the 60-year
170.
journey of hope and final success-lessons learned and future
[34] Singh SK, Plieskatt J, Chourasia BK, et al. Preclinical develop-
prospects[J]. Trop Med Health, 2023, 51(1): 29.
ment of a Pfs230-Pfs48/45 chimeric malaria transmission-
[45] Yamamoto Y, Fabbri C, Okuhara D, et al. A two-dose viral-
blocking vaccine[J]. NPJ Vaccines, 2021, 6(1): 120.
vectored Plasmodium vivax multistage vaccine confers durable
[35] Singh SK, Plieskatt J, Chourasia BK, et al. A reproducible and
protection and transmission-blockade in a pre-clinical study[J].
scalable process for manufacturing a Pfs48/45 based Plasmodi-
Front Immunol, 2024, 15: 1372584.
um falciparum transmission-blocking vaccine[J]. Front Im-
[46] Hasyim AA, Iyori M, Mizuno T, et al. Adeno-associated virus-
munol, 2021, 11: 606266.
based malaria booster vaccine following attenuated replication-
[36] Tiono AB, Plieskatt JL, Ouedraogo A, et al. A randomized first-
competent vaccinia virus LC16m8Δ priming[J]. Parasitol Int,
in-human phase I trial of differentially adjuvanted Pfs48/45
2023, 92: 102652.
malaria vaccines in Burkinabé adults[J]. J Clin Invest, 2024,
[47] Rampling T, Ewer KJ, Bowyer G, et al. Safety and efficacy of
134(7): e175707.
novel malaria vaccine regimens of RTS, S/AS01B alone, or
[37] Dickey TH, Gupta R, McAleese H, et al. Design of a stabilized
with concomitant ChAd63-MVA-vectored vaccines expressing
non-glycosylated Pfs48/45 antigen enables a potent malaria
ME-TRAP[J]. NPJ Vaccines, 2018, 3: 49.
transmission-blocking nanoparticle vaccine[J]. NPJ Vaccines,
[48] Wu RL, Idris AH, Berkowitz NM, et al. Low-dose subcuta-
2023, 8(1): 20.
neous or intravenous monoclonal antibody to prevent
[38] Arévalo-Herrera M, Gaitán X, Larmat-Delgado M, et al. Ran-
domized clinical trial to assess the protective efficacy of a Plas- malaria[J]. N Engl J Med, 2022, 387(5): 397-407.
modium vivax CS synthetic vaccine[J]. Nat Commun, 2022, [49] Kayentao K, Ongoiba A, Preston AC, et al. Subcutaneous ad-
13(1): 1603. ministration of a monoclonal antibody to prevent malaria[J]. N
[39] Martinez FJ, White M, Guillotte-Blisnick M, et al. PvDBPII Engl J Med, 2024, 390(17): 1549-1559.
elicits multiple antibody-mediated mechanisms that reduce [50] Miura K, Tachibana M, Takashima E, et al. Malaria transmis-
growth in a Plasmodium vivax challenge trial[J]. NPJ Vaccines, sion-blocking vaccines: wheat germ cell-free technology can ac-
2024, 9(1): 10. celerate vaccine development[J]. Expert Rev Vaccines, 2019,
[40] Payne RO, Silk SE, Elias SC, et al. Human vaccination against 18(10): 1017-1027.